Education
About Us
Working with TipRanks
Follow Us
Immuneering (IMRX)
NASDAQ:IMRX
IMRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.00 - $6.65
Previous CloseN/A
Volume3.55M
Average Volume (3M)284.02K
Market Cap
$47.20M
Enterprise Value$27.89M
Total Cash (Recent Filing)-$13.78M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.21
Next Earnings
May 13, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding31,050,447
10 Day Avg. Volume212,274
30 Day Avg. Volume284,019
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2458.16
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-36.50
Enterprise Value/Ebitda-0.46
Forecast
1Y Price Target
$10.00Price Target Upside557.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical CollaborationsPartnering with a global pharmaceutical company like Regeneron provides external validation of Immuneering's technology.
Efficacy DataInitial Phase 2a efficacy data from IMM-1-104 in combination with chemotherapy shows a promising overall response rate of 40% and a disease control rate of 80%.
Bears Say
Stock PerformanceDespite the positive data, the stock has surprisingly declined since the announcement.
---
Ownership Overview
30.64% Insiders
6.06% Mutual Funds
1.23% Other Institutional Investors
58.47% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IMRX FAQ
What was Immuneering’s price range in the past 12 months?
Immuneering lowest stock price was $1.00 and its highest was $6.65 in the past 12 months.
What is Immuneering’s market cap?
Immuneering’s market cap is $47.20M.
When is Immuneering’s upcoming earnings report date?
Immuneering’s upcoming earnings report date is May 13, 2025 which is in 63 days.
How were Immuneering’s earnings last quarter?
Currently, no data Available
Is Immuneering overvalued?
According to Wall Street analysts Immuneering’s price is currently Undervalued.
Does Immuneering pay dividends?
Immuneering does not currently pay dividends.
What is Immuneering’s EPS estimate?
Immuneering’s EPS estimate is -0.45.
How many shares outstanding does Immuneering have?
Immuneering has 31,050,447 shares outstanding.
What happened to Immuneering’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Immuneering?
Among the largest hedge funds holding Immuneering’s share is Perceptive Advisors LLC. It holds Immuneering’s shares valued at 0.
---
Immuneering Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (557.89% Upside)
$10.00 (557.89% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 9.6%
Last 30 Days ▼ 9.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.24%
12-Months-Change
Fundamentals
Return on Equity
-71.81%
Trailing 12-Months
Asset Growth
-39.80%
Trailing 12-Months
Company Description
Immuneering
Immuneering Corpbiopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.
---
IMRX Stock 12 Month Forecast
Average Price Target
$10.00
▲(557.89% Upside)
Technical Analysis
Best Analysts Covering IMRX
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
-20.28%
reiterated a buy rating 6 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -20.28% per trade.
---